The increase was primarily attributable to (i) a $5.5 million increase in non-cash stock based compensation expense associated with equity awards granted at higher market prices, (ii) a $2.8 million increase in professional fees associated with build-out of our corporate infrastructure to support the continued growth, and (iii) a $1.1 million increase in payroll related costs related to increased headcount.

filing / Aug 10, 2026 / receipt

activities supporting these programs, and (ii) increased personnel-related costs, including higher non-cash stock-based compensation expense associated with equity awards granted at higher market prices and increased headcount to support our expanding development activities.

filing / Aug 10, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize palazestrant, OP-3136, or any future product candidates we may develop.

filing / Aug 10, 2026 / receipt

Office lease deposits 595 464 Property and equipment, net 382 274 Total $ 16,064 $ 16,832 18 Table of Contents 6.

filing / Aug 10, 2026 / receipt

On August 23, 2023, the Company entered into a lease agreement with The Cambridge Redevelopment Authority to lease approximately 4,020 square feet of office space in Cambridge, Massachusetts (the “Cambridge Lease Agreement”).

filing / Aug 10, 2026 / receipt

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in European countries, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as palazestrant, OP-3136, or any future product candidates we may deve

filing / Aug 10, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize palazestrant, OP-3136, or any future product candidates we may develop.

filing / May 12, 2026 / receipt

Office lease deposits - 464 Total $ 16,495 $ 16,832 6. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): March 31, December 31, 2026 2025 Accrued research and development related costs $ 35,396 $ 29,286 Accrued payroll related costs 2,775 1,149 Accrued employee bonuses 2,202 8,253 Accrued corporate r

filing / May 12, 2026 / receipt

On August 23, 2023, the Company entered into a lease agreement with The Cambridge Redevelopment Authority to lease approximately 4,020 square feet of office space in Cambridge, Massachusetts (the “Cambridge Lease Agreement”).

filing / May 12, 2026 / receipt

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in European countries, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as palazestrant, OP-3136, or any future product candidates we may deve

filing / May 12, 2026 / receipt

Director, Clinical Supply Chain | {"ats": "greenhouse", "city": "San Francisco", "state": "CA", "job_id": "6181924004", "remote": false, "category": "other", "function": "operations", "location": "San

company_statement / Sep 4, 2026 / receipt

Director, Clinical Supply Chain | {"ats": "greenhouse", "city": "Boston", "state": "MA", "job_id": "6181925004", "remote": false, "category": "other", "function": "operations", "location": "Boston, Ma

company_statement / Sep 4, 2026 / receipt